The paradox of immunosuppressants and COVID-19

Guang Shing Cheng; Scott E. Evans

doi:10.1183/13993003.02828-2021

The paradox of immunosuppressants and COVID-19

Guang Shing Cheng, Scott E. Evans

Pulmonary Medicine

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Original language	English (US)
Article number	2102828
Journal	The European respiratory journal
Volume	59
Issue number	4
DOIs	https://doi.org/10.1183/13993003.02828-2021
State	Published - Apr 1 2022

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1183/13993003.02828-2021

Cite this

@article{1c886fb369894817aca86bdb8ef09b1f,

title = "The paradox of immunosuppressants and COVID-19",

author = "Cheng, {Guang Shing} and Evans, {Scott E.}",

note = "Funding Information: Conflict of interest: G-S. Cheng reports institutional funds for pilot research from NIH/NCI Cancer Center support grant P30 CA015704; participation on consulting relationship for endpoint adjudication committee at Janssen Pharmaceuticals; data safety monitoring board member for phase I study of DVX201, an allogeneic natural killer (NK) Cell therapy for subjects hospitalised for COVID-19; board member for Firland Foundation; outside the submitted work. S.E. Evans reports grants from US NIH; royalties and founders{\textquoteright} stock from Pulmotect, Inc.; outside the submitted work.",

year = "2022",

month = apr,

day = "1",

doi = "10.1183/13993003.02828-2021",

language = "English (US)",

volume = "59",

journal = "The European respiratory journal",

issn = "0903-1936",

number = "4",

}

TY - JOUR

T1 - The paradox of immunosuppressants and COVID-19

AU - Cheng, Guang Shing

AU - Evans, Scott E.

N1 - Funding Information: Conflict of interest: G-S. Cheng reports institutional funds for pilot research from NIH/NCI Cancer Center support grant P30 CA015704; participation on consulting relationship for endpoint adjudication committee at Janssen Pharmaceuticals; data safety monitoring board member for phase I study of DVX201, an allogeneic natural killer (NK) Cell therapy for subjects hospitalised for COVID-19; board member for Firland Foundation; outside the submitted work. S.E. Evans reports grants from US NIH; royalties and founders’ stock from Pulmotect, Inc.; outside the submitted work.

PY - 2022/4/1

Y1 - 2022/4/1

UR - http://www.scopus.com/inward/record.url?scp=85129270157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85129270157&partnerID=8YFLogxK

U2 - 10.1183/13993003.02828-2021

DO - 10.1183/13993003.02828-2021

M3 - Review article

C2 - 34795039

AN - SCOPUS:85129270157

SN - 0903-1936

VL - 59

JO - The European respiratory journal

JF - The European respiratory journal

IS - 4

M1 - 2102828

ER -

The paradox of immunosuppressants and COVID-19

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this